Skip to main content

Low-dose erlotinib seems feasible for frail, elderly patients with NSCLC

Primary tabs

View
Get Stamp Tags
Published Locations

Breadcrumb

Home
Low-dose erlotinib seems feasible for frail, elderly patients with NSCLC

User login

Username

Password

Reset your password

Type	Lead	score